- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Benjamin Click, MD: Biosimilars in IBD
Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how biosimilars fit in the treatment paradigm for inflammatory bowel disease (IBD).
Transcript
Yes, so I think biosimilars have the opportunity to potentially change the biologic landscape. Biosimilars are just starting to come into routine clinical practice in the United States. They’ve been used for several more years in European and non-American countries, so a lot of the more long-term experience coming from the European colleagues is very encouraging.
We are starting to routinely use biosimilars, mostly for infliximab at this point in time, though we do hope to see a biosimilar for adalimumab hit the market in the next several years. So I think there’s a lot of potential cost savings opportunity when we think about healthcare costs in the United States and how we can potentially impact those as well.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
